WO2007038630A3 - N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof - Google Patents

N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof Download PDF

Info

Publication number
WO2007038630A3
WO2007038630A3 PCT/US2006/037742 US2006037742W WO2007038630A3 WO 2007038630 A3 WO2007038630 A3 WO 2007038630A3 US 2006037742 W US2006037742 W US 2006037742W WO 2007038630 A3 WO2007038630 A3 WO 2007038630A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted pyridyl
methods
benzyl
pyridyl porphyrin
disease
Prior art date
Application number
PCT/US2006/037742
Other languages
French (fr)
Other versions
WO2007038630A2 (en
Inventor
William Williams
Original Assignee
Inotek Pharmaceuticals Corp
William Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp, William Williams filed Critical Inotek Pharmaceuticals Corp
Priority to JP2008533585A priority Critical patent/JP2009510083A/en
Priority to AU2006294655A priority patent/AU2006294655A1/en
Priority to EP06815616A priority patent/EP1928467A4/en
Priority to CA002622988A priority patent/CA2622988A1/en
Publication of WO2007038630A2 publication Critical patent/WO2007038630A2/en
Publication of WO2007038630A3 publication Critical patent/WO2007038630A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)

Abstract

The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation- induced injury, and methods for prolonging the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of an N-Benzyl- Substituted Pyridyl Porphyrin Compound.
PCT/US2006/037742 2005-09-28 2006-09-26 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof WO2007038630A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008533585A JP2009510083A (en) 2005-09-28 2006-09-26 N-benzyl-substituted pyridylporphyrin compound and method of using the same
AU2006294655A AU2006294655A1 (en) 2005-09-28 2006-09-26 N-Benzyl substituted pyridyl porphyrin compounds and methods of use thereof
EP06815616A EP1928467A4 (en) 2005-09-28 2006-09-26 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
CA002622988A CA2622988A1 (en) 2005-09-28 2006-09-26 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72138805P 2005-09-28 2005-09-28
US60/721,388 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007038630A2 WO2007038630A2 (en) 2007-04-05
WO2007038630A3 true WO2007038630A3 (en) 2007-10-25

Family

ID=37900440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037742 WO2007038630A2 (en) 2005-09-28 2006-09-26 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof

Country Status (7)

Country Link
US (2) US7642250B2 (en)
EP (1) EP1928467A4 (en)
JP (1) JP2009510083A (en)
AU (1) AU2006294655A1 (en)
CA (1) CA2622988A1 (en)
WO (1) WO2007038630A2 (en)
ZA (1) ZA200803580B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561266A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US20110111007A1 (en) * 2005-04-29 2011-05-12 Mcginnis James F Inhibition of retinal cell degeneration or neovascularization by cerium oxide nanoparticles
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
US20090257999A1 (en) * 2007-12-31 2009-10-15 Inotek Pharmaceuticals Corporation Method of preventing contrast-induced nephropathy
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US20120065181A1 (en) * 2009-05-26 2012-03-15 Warner David S Method of providing neuroprotection using substituted porphyrins
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
US8877207B2 (en) 2010-09-17 2014-11-04 University Of Central Florida Research Foundation, Inc. Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods
US9274060B1 (en) 2011-01-13 2016-03-01 Mocon, Inc. Methods for transmembrane measurement of oxygen concentration and monitoring changes in oxygen concentration within a space enclosed by a membrane employing a photoluminescent transmembrane oxygen probe
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
CN102408452B (en) * 2011-12-13 2014-09-03 中山大学 Tetrapyridylporphine bridged crossed tetra-palladium complexes, and preparation method and antitumor activity thereof
WO2013151698A1 (en) 2012-04-04 2013-10-10 Duke University Methods for using cerium oxide nanoparticles to mitigate or protect against radiation injury
US9223210B2 (en) 2012-04-09 2015-12-29 Toyo Gosei Co., Ltd. Photosensitive compound, photosensitive resin, and photosensitive composition
US8658429B1 (en) 2012-08-06 2014-02-25 Mocon, Inc. Photoluminescent oxygen probe tack
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
US9733187B2 (en) * 2015-03-06 2017-08-15 King Saud University Method of detecting bladder cancer by optical analysis of bodily fluids
WO2022047196A1 (en) * 2020-08-28 2022-03-03 Nisibis, Llc-S Pten inhibitors for treatment and prevention of bone marrow loss
CN115792075B (en) * 2021-09-10 2023-11-03 江苏瑞科生物技术股份有限公司 Detection method of 4' -monophosphoryl lipid A compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573258B2 (en) * 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
US6730666B1 (en) * 1998-11-08 2004-05-04 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US6916799B2 (en) * 1997-11-03 2005-07-12 Duke University Substituted porphyrins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635304T2 (en) 1995-06-07 2006-07-20 Duke University FAENGER FOR OXIDANTS
US6087493A (en) 1997-02-05 2000-07-11 Regents Of The University Of Texas System Porphyrin compounds as telomerase inhibitors
US20030032634A1 (en) 2001-06-01 2003-02-13 Piganelli Jon D. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US7485721B2 (en) * 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US7807825B2 (en) 2004-02-09 2010-10-05 Duke University Substituted porphyrins
CA2561266A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US8334377B2 (en) 2006-10-06 2012-12-18 The Trustees Of Princeton University Porphyrin catalysts and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916799B2 (en) * 1997-11-03 2005-07-12 Duke University Substituted porphyrins
US6730666B1 (en) * 1998-11-08 2004-05-04 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US6573258B2 (en) * 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents

Also Published As

Publication number Publication date
EP1928467A4 (en) 2009-11-04
JP2009510083A (en) 2009-03-12
US20100113386A1 (en) 2010-05-06
US20070072825A1 (en) 2007-03-29
WO2007038630A2 (en) 2007-04-05
EP1928467A2 (en) 2008-06-11
US7642250B2 (en) 2010-01-05
CA2622988A1 (en) 2007-04-05
AU2006294655A1 (en) 2007-04-05
ZA200803580B (en) 2009-01-28

Similar Documents

Publication Publication Date Title
WO2007038630A3 (en) N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
WO2005097123A3 (en) Pyridyl-substituted porphyrin compounds and methods of use thereof
HK1107816A1 (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer meleimide
WO2006093666A3 (en) Isoqunoline compounds and methods of use thereof
WO2008118391A3 (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2009038779A3 (en) Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
MX2007005940A (en) Triazole compounds that modulate hsp90 activity.
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
WO2008048589A3 (en) Compounds and methods for treatment of hcv
WO2006125555A3 (en) Quinazolinones
WO2006026747A3 (en) Diphenylethylene compounds and uses thereof
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
WO2008106619A3 (en) Indenoisoquinolinone analogs and methods of use thereof
WO2006041855A3 (en) Compositions and methods using apocynin compounds and nitric oxide donors
WO2006088903A3 (en) Pyrazole compounds
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
WO2007054965A3 (en) Process for preparation of tetrazoles from aromatic cyano derivatives
WO2005117545A3 (en) Nitric oxide dioxygenase inhibitors
WO2008057534A3 (en) Methods and compositions for organ protection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2622988

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008533585

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006815616

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006294655

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3241/DELNP/2008

Country of ref document: IN